NPPB and heart failure: The primary hierarchical outcome, which included cardiovascular death, heart failure hospitalizations, urgent visits, and a 25% reduction in NT-proBNP, showed a significant treatment effect favoring sacubitril/valsartan (WR, 1.46; 95% CI, 1.08–1.97) in the subgroup with ejection fraction ≤60%.